15/03/2018
Oxthera announces the randomization of the first patient into its phase III EPHEX study with Oxabact
Oxthera AB, a Stockholm-based privately-held biopharmaceutical company with a product in late stage clinical development focusing on Primary hyperoxaluria (PH), announces [....]
